Deciphera Pharmaceuticals Inc DCPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:21 AM EDT
15.66quote price arrow up+0.48 (+3.19%)
Volume
69,890
52 week range
9.90 - 17.73
Loading...
  • Open15.37
  • Day High15.68
  • Day Low15.25
  • Prev Close15.18
  • 52 Week High17.73
  • 52 Week High Date03/01/24
  • 52 Week Low9.90
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap1.266B
  • Shares Out80.80M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.38
  • YTD % Change-3.53

KEY STATS

  • Open15.37
  • Day High15.68
  • Day Low15.25
  • Prev Close15.18
  • 52 Week High17.73
  • 52 Week High Date03/01/24
  • 52 Week Low9.90
  • 52 Week Low Date10/25/23
  • Market Cap1.266B
  • Shares Out80.80M
  • 10 Day Average Volume0.58M
  • Dividend-
  • Dividend Yield-
  • Beta0.38
  • YTD % Change-3.53

RATIOS/PROFITABILITY

  • EPS (TTM)-2.29
  • P/E (TTM)-6.83
  • Fwd P/E (NTM)-7.25
  • EBITDA (TTM)-208.858M
  • ROE (TTM)-56.29%
  • Revenue (TTM)163.356M
  • Gross Margin (TTM)97.72%
  • Net Margin (TTM)-119.34%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Deciphera Pharmaceuticals Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal...
Ron Squarer
Independent Chairman of the Board
Steven Hoerter
President, Chief Executive Officer, Director
Thomas Kelly J.D.
Chief Financial Officer, Executive Vice President, Treasurer
Dashyant Dhanak Ph.D.
Executive Vice President, Chief Scientific Officer
Matthew Sherman M.D.
Executive Vice President, Chief Medical Officer
Address
200 Smith St
Waltham, MA
02451-0099
United States

Top Peers

SYMBOLLASTCHG%CHG
MIRM
Mirum Pharmaceuticals Inc
25.41+0.29+1.15%
LGND
Ligand Pharmaceuticals Inc
72.22+0.95+1.33%
XNCR
Xencor Inc
22.23-0.19-0.85%
MNKD
MannKind Corp
4.59-0.04-0.76%
PACB
Pacific Biosciences of California Inc
3.78+0.06+1.61%